GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Longduoduo Co Ltd (OTCPK:LDDD) » Definitions » Sloan Ratio %

Longduoduo Co (Longduoduo Co) Sloan Ratio % : 24.70% (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Longduoduo Co Sloan Ratio %?

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

Longduoduo Co's Sloan Ratio for the quarter that ended in Mar. 2024 was 24.70%.

Warning Sign:

When sloan ratio (-59.2)% higher than 25% or lower than -25%, earnings are more likely to be made up of accruals.

As of Mar. 2024, Longduoduo Co has a Sloan Ratio of 24.70%, indicating earnings are more likely to be made up of accruals.


Longduoduo Co Sloan Ratio % Historical Data

The historical data trend for Longduoduo Co's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Longduoduo Co Sloan Ratio % Chart

Longduoduo Co Annual Data
Trend Jun21 Jun22 Jun23
Sloan Ratio %
-118.48 -1,216.69 -59.20

Longduoduo Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Sloan Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -173.46 -59.27 13.57 -56.82 24.70

Competitive Comparison of Longduoduo Co's Sloan Ratio %

For the Diagnostics & Research subindustry, Longduoduo Co's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Longduoduo Co's Sloan Ratio % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Longduoduo Co's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where Longduoduo Co's Sloan Ratio % falls into.



Longduoduo Co Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

Longduoduo Co's Sloan Ratio for the fiscal year that ended in Jun. 2023 is calculated as

Sloan Ratio=(Net Income (A: Jun. 2023 )-Cash Flow from Operations (A: Jun. 2023 )
-Cash Flow from Investing (A: Jun. 2023 ))/Total Assets (A: Jun. 2023 )
=(-0.039-0.965
--0.126)/1.483
=-59.20%

Longduoduo Co's Sloan Ratio for the quarter that ended in Mar. 2024 is calculated as

Sloan Ratio=(Net Income (TTM)-Cash Flow from Operations (TTM))
-Cash Flow from Investing (TTM))/Total Assets (Q: Mar. 2024 )
=(1.774-1.446
--0.3)/2.542
=24.70%

Longduoduo Co's Net Income for the trailing twelve months (TTM) ended in Mar. 2024 was 0.829 (Jun. 2023 ) + 0.284 (Sep. 2023 ) + 0.149 (Dec. 2023 ) + 0.512 (Mar. 2024 ) = $1.77 Mil.
Longduoduo Co's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2024 was 0.457 (Jun. 2023 ) + -0.383 (Sep. 2023 ) + 1.987 (Dec. 2023 ) + -0.615 (Mar. 2024 ) = $1.45 Mil.
Longduoduo Co's Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2024 was -0.051 (Jun. 2023 ) + -0.021 (Sep. 2023 ) + -0.23 (Dec. 2023 ) + 0.002 (Mar. 2024 ) = $-0.30 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Longduoduo Co  (OTCPK:LDDD) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Mar. 2024, Longduoduo Co has a Sloan Ratio of 24.70%, indicating earnings are more likely to be made up of accruals.


Longduoduo Co Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of Longduoduo Co's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


Longduoduo Co (Longduoduo Co) Business Description

Traded in Other Exchanges
N/A
Address
Ordos Street, 419, Floor 4, Comprehensive Building, Second Light Hospital, Yuquan District, Inner Mongolia, Hohhot, CHN, 010000
Longduoduo Co Ltd through its operating subsidiaries engaged in the business of providing preventive healthcare solutions. It provides a wide range of comprehensive preventive healthcare services including disease screening, healthcare treatments, healthcare products, and other services. The company mainly focuses on the prevention of myocardial infarction, cerebral infarction, hemiplegia, and cardiovascular and cerebrovascular diseases. The company's revenues are generated from its customers in the People's Republic of China.

Longduoduo Co (Longduoduo Co) Headlines

No Headlines